KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)
Provided By GlobeNewswire
Last update: Jul 9, 2025
-- Topline results from the CHASE trial expected by end of Q3 2025 --
-- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results --
Read more at globenewswire.com
